Meeting
2011 ASCO Annual Meeting
Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma.
Authors
J. R. Merchan
University of Miami Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL
J. R. Merchan , H. C. Pitot , R. Qin , G. Liu , T. R. Fitch , W. J. Maples , J. Picus , C. Erlichman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT00112840
Citation
J Clin Oncol 29: 2011 (suppl; abstr 4548)
Abstract #
4548
Poster Bd #
3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A phase I/II study to evaluate the safety, pharmacodynamics, and efficacy of entinostat in combination with atezolizumab and bevacizumab in patients with renal cell carcinoma.
First Author: Roberto Pili
Poster
2019 Gastrointestinal Cancers Symposium
Phase II multicenter pilot study of safety, efficacy, and immune cell profiling in advanced hepatocellular carcinoma (HCC) on combination of sorafenib (SOR) plus nivolumab (NIVO).
First Author: Bridget Keenan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial.
First Author: Jaekyung Cheon
Poster
2022 ASCO Genitourinary Cancers Symposium
PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC).
First Author: Martin H Voss